Loading...

VOR VOR BIOPHARMA INC Product Launches 8-K Filing

VR B

VR

VOR BIOPHARMA INC

(VOR)

2025 8-K

Private Placement Agreement

Financial Update

Management Change

Funding Announcement

Stock Option Repricing

Equity Offering Details

Management Changes

Clinical Trial Data

Stock Split Update

Corporate Presentation Update

Management Changes

Stockholder Approval

Licensing Agreement

Equity Offerings

Workforce Reduction

Noncompliance with Listing ...

Management Change

Stock Option Repricing

Board Appointment

Private Placement

Clinical Data Update

CFO Appointment

Resignation and Appointment

Equity Incentive Plan Amend...

Appointment of Director

Clinical Update

Annual Meeting of Stockholders

Resignation of Director

Clinical Update

External Links:

On October 28, 2025, Vor Biopharma Inc. announced results from a 48-week Phase 3 clinical trial in China for telitacicept, targeting primary Sjögren’s disease. This filing is significant for investors, reflecting on potential advancements in treatment options.

AI Assistant

VOR BIOPHARMA INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.